Objective:This study aimed to investigate the relationship between circulating tumor DNA and epithelial ovarian cancer.Methods:Twenty-seven cases with epithelial ovarian cancer in changle people's hospital in shan...Objective:This study aimed to investigate the relationship between circulating tumor DNA and epithelial ovarian cancer.Methods:Twenty-seven cases with epithelial ovarian cancer in changle people's hospital in shandong province were collected.Blood samples before operation were collected to detect circulating tumor DNA.Results:There are 22 ctDNA positive cases,with a proportion of 81.5%(22/27).Proportion of ctDNA positive patients before operation in the early and advanced stage was 60%and 94.1%respectively,with a statistically significant difference(P<0.05).The difference of proportion of ctDNA positive patients before operation in the subgroup analysis based on clinical stage,histological grading,pathological types,and tumor size was statistically significant(P<0.05).Conclusion:CtDNA is a promising tumor marker associated with epithelial ovarian cancer.展开更多
Glioma,the most common primary intracranial tumor,has high morbidity and mortality.The detection of circulating tumor cells(CTCs)is an important part of the liquid biopsy of gliomas.CTCs,carrying the genetic and biolo...Glioma,the most common primary intracranial tumor,has high morbidity and mortality.The detection of circulating tumor cells(CTCs)is an important part of the liquid biopsy of gliomas.CTCs,carrying the genetic and biological information of tumor tissue,provide a new perspective and dimension for the study of tumor metastasis,progression,chemotherapy sensitivity and drug resistance.Cerebrospinal fluid(CSF)circulates through the ventricle and spinal cord cistern,which can better maintain the original information of tumor cells compared with the complicated environments of tissues and plasma.Study on the dynamic changes of CTCs in the CSF of the central nervous system(CNS)is relatively rare.However,the analysis of CTCs in CSF can be used to guide the treatment of gliomas and reveal the patho-physiological and genetic mechanisms of tumor cell metastasis to the CSF.This paper reviews the progress in the research on CTC detection in gliomas.展开更多
Background Phenotypic and genotypic heterogeneity is a known feature of many cancers.Whether serum tumor marker kinds vary and change following chemotherapy is still unclear.The aim of this study was to investigate wh...Background Phenotypic and genotypic heterogeneity is a known feature of many cancers.Whether serum tumor marker kinds vary and change following chemotherapy is still unclear.The aim of this study was to investigate whether there is a change in the expression of serum tumor markers following chemotherapy,and the potential clinical significance in patients with epithelial ovarian carcinoma （EOC） or primary serous peritoneal carcinoma （PSPC）.Methods Samples were collected before surgery,during chemotherapy and during follow-up for enzyme-linked immunosorbent assay （ELISA）-based evaluation of serum CA-125,CA19-9 and CP2 levels in patients with EOC or PSPC who had received primary debulking surgery followed by adjuvant chemotherapy.In total,72 patients were examined,including 37 patients with recurrent lesions and 35 patients receiving first-line chemotherapy.Results In 35 de novo patients,20% （7/35） demonstrated a significant changed serum tumor marker kinds among whom the patients with mucinous carcinoma （57.1%,4/7） showed resistance to chemotherapy.In the 37 recurrent patients,51.4% （19/37） had changed serum tumor markers,of whom 57.9% （11/19） presented with serous carcinoma.There was no significant difference in median progression-free survival or overall survival in patients with drug-sensitive or drug-resistant recurrence in patients with changed tumor marker kinds relative to those with unchanged markers.However,for patients with changed serum tumor markers there was a trend towards prolonged survival compared with the unchanged serum tumor marker group.In the 17 patients with secondary recurrence,37.5% （6/17） had changed tumor marker levels.The ratios of CA-125/CP2 and CA-125/CA19-9 were significantly different after either chemotherapy or recurrence.Conclusions Serum tumor marker expression in patients with EOC or PSPC may change after chemotherapy or recurrence,indicating that in addition to the markers that are abnormal before surgery,those markers that are normalshould also be monitored during chemotherapy and follow-up.展开更多
Epithelial ovarian cancer(EOC)is the most lethal gynaecological malignancy in the western world.The majority of women presenting with the disease are asymptomatic and it has been dubbed the“silent killer”.To date th...Epithelial ovarian cancer(EOC)is the most lethal gynaecological malignancy in the western world.The majority of women presenting with the disease are asymptomatic and it has been dubbed the“silent killer”.To date there is no effective minimally invasive method of stratifying those with the disease or screening for the disease in the general population.Recent molecular and pathological discoveries,along with the advancement of scientific technology,means there is a real possibility of having disease-specific liquid biopsies available within the clinical environment in the near future.In this review we discuss these discoveries,particularly in relation to the most common and aggressive form of EOC,and their role in making this possibility a reality.展开更多
AIM： To determine DNA aneuploidy in mucosal biopsies of achalasia patients for subsequent rapid diagnosis. METHODS： Biopsies from the middle third of the esophagus were obtained in 15 patients with achalasia. Immuno...AIM： To determine DNA aneuploidy in mucosal biopsies of achalasia patients for subsequent rapid diagnosis. METHODS： Biopsies from the middle third of the esophagus were obtained in 15 patients with achalasia. Immunohistochemical staining was carried out with monoclonal antibodies MIB-1 for Ki67 and PAb 1801 for p53, in addition to the conventional histologic examination for dysplasia. Nuclei of fresh biopsy material were enzymatically and mechanically isolated, and the DNA content was determined with image cytometry after Feulgen staining. DNA grading of malignancy was assessed according to Boecking to determine the variability of DNA values noted around the normal diploid peak. Further indices measured included the aneuploid rate, and the 5c-, 7c- and 9c-exceeding rate. RESULTS： The histological examination did not demonstrate dysplasia; while MIB-1 （basal） showed a positive reaction in 8/15 achalasia specimens, p53 was negative in all specimens. Image cytometric DNA analysis detected aneuploidy in 4/15 （26.7%） specimens. Samples from 15 patients with squamous cell carcinoma as well as specimens obtained exclusively 2 cm proximal to the tumor served as reference tests. All carcinomas （15/15） as well as 9 of the peritumoral samples （9/15） were aneuploid. The comparison of biopsies from achalasia patients with peritumoral and carcinoma specimens revealed statistically significant differences regarding the aneuploid rate （diploid： P 〈 0.0001; tetraploid： P = 0.001）, grading of malignancy according to Boecking （P 〈 0.0001） and the 5c- （P 〈 0.0001）, 7c-（P 〈 0.0001）, and 9c- （P = 0.0001） exceeding rate with progredient DNA alterations in the respective order. CONCLUSION： The finding that DNA aneuploidy was identified by image cytometry in esophageal specimens of patients with achalasia, which may be due to specific chromosomal alterations presenting as precancerous lesions in 27% of patients, leads us to conclude that image cytometry represents a valuable screening tool.展开更多
目的:探讨人食管癌相关基因4(esophageal cancer related gene 4,ECRG4)基因启动子区域在卵巢癌组织中的甲基化状态及临床意义。方法:应用甲基化特异性PCR检测ECRG4基因启动子在50例卵巢癌组织和10例正常卵巢组织中的甲基化状态并结合...目的:探讨人食管癌相关基因4(esophageal cancer related gene 4,ECRG4)基因启动子区域在卵巢癌组织中的甲基化状态及临床意义。方法:应用甲基化特异性PCR检测ECRG4基因启动子在50例卵巢癌组织和10例正常卵巢组织中的甲基化状态并结合临床病理资料进行分析。结果:在卵巢癌组织中ECRG4甲基化阳性率为36%(18/50),正常卵巢组织未出现ECRG4甲基化。ECRG4甲基化与肿瘤淋巴结转移及Ki-67表达密切相关(P<0.05)。结论:ECRG4甲基化可能是参与卵巢癌发展的重要分子事件。展开更多
目的通过对患者血浆游离DNA的定量检测,探索一种可用于卵巢上皮性癌早期诊断和疗效监控的新方法。方法2001年4月至2003年2月上海市肿瘤研究所等单位以微量基因组抽提试剂盒抽提血浆DNA,以SYBR Green I斑点荧光染色法分别检测93例卵巢上...目的通过对患者血浆游离DNA的定量检测,探索一种可用于卵巢上皮性癌早期诊断和疗效监控的新方法。方法2001年4月至2003年2月上海市肿瘤研究所等单位以微量基因组抽提试剂盒抽提血浆DNA,以SYBR Green I斑点荧光染色法分别检测93例卵巢上皮性癌、25例卵巢良性肿瘤及100例健康对照标本血浆游离DNA含量。结果卵巢上皮性癌血浆游离DNA质量浓度为(82.1±60.6)μg/L,卵巢良性肿瘤为(21.1±17.6)μg/L,健康对照组为(14.9±8.2)μg/L,卵巢上皮性癌患者血浆游离DNA质量浓度明显高于正常对照及卵巢良性肿瘤,差异有显著性(P<0.001)。血浆游离DNA质量浓度与病理类型及组织学分级无关,但与临床分期相关,IV期癌较其他三期升高明显(P=0.016)。在I期卵巢上皮性癌患者中,血浆游离DNA质量浓度已达(68.8±46.1)μg/L,显著高于卵巢良性肿瘤和健康对照人员(P<0.001)。结论卵巢上皮性癌游离DNA定量检测有可能成为一种新的卵巢上皮性癌血浆标志物检测方法。展开更多
文摘Objective:This study aimed to investigate the relationship between circulating tumor DNA and epithelial ovarian cancer.Methods:Twenty-seven cases with epithelial ovarian cancer in changle people's hospital in shandong province were collected.Blood samples before operation were collected to detect circulating tumor DNA.Results:There are 22 ctDNA positive cases,with a proportion of 81.5%(22/27).Proportion of ctDNA positive patients before operation in the early and advanced stage was 60%and 94.1%respectively,with a statistically significant difference(P<0.05).The difference of proportion of ctDNA positive patients before operation in the subgroup analysis based on clinical stage,histological grading,pathological types,and tumor size was statistically significant(P<0.05).Conclusion:CtDNA is a promising tumor marker associated with epithelial ovarian cancer.
文摘Glioma,the most common primary intracranial tumor,has high morbidity and mortality.The detection of circulating tumor cells(CTCs)is an important part of the liquid biopsy of gliomas.CTCs,carrying the genetic and biological information of tumor tissue,provide a new perspective and dimension for the study of tumor metastasis,progression,chemotherapy sensitivity and drug resistance.Cerebrospinal fluid(CSF)circulates through the ventricle and spinal cord cistern,which can better maintain the original information of tumor cells compared with the complicated environments of tissues and plasma.Study on the dynamic changes of CTCs in the CSF of the central nervous system(CNS)is relatively rare.However,the analysis of CTCs in CSF can be used to guide the treatment of gliomas and reveal the patho-physiological and genetic mechanisms of tumor cell metastasis to the CSF.This paper reviews the progress in the research on CTC detection in gliomas.
文摘Background Phenotypic and genotypic heterogeneity is a known feature of many cancers.Whether serum tumor marker kinds vary and change following chemotherapy is still unclear.The aim of this study was to investigate whether there is a change in the expression of serum tumor markers following chemotherapy,and the potential clinical significance in patients with epithelial ovarian carcinoma （EOC） or primary serous peritoneal carcinoma （PSPC）.Methods Samples were collected before surgery,during chemotherapy and during follow-up for enzyme-linked immunosorbent assay （ELISA）-based evaluation of serum CA-125,CA19-9 and CP2 levels in patients with EOC or PSPC who had received primary debulking surgery followed by adjuvant chemotherapy.In total,72 patients were examined,including 37 patients with recurrent lesions and 35 patients receiving first-line chemotherapy.Results In 35 de novo patients,20% （7/35） demonstrated a significant changed serum tumor marker kinds among whom the patients with mucinous carcinoma （57.1%,4/7） showed resistance to chemotherapy.In the 37 recurrent patients,51.4% （19/37） had changed serum tumor markers,of whom 57.9% （11/19） presented with serous carcinoma.There was no significant difference in median progression-free survival or overall survival in patients with drug-sensitive or drug-resistant recurrence in patients with changed tumor marker kinds relative to those with unchanged markers.However,for patients with changed serum tumor markers there was a trend towards prolonged survival compared with the unchanged serum tumor marker group.In the 17 patients with secondary recurrence,37.5% （6/17） had changed tumor marker levels.The ratios of CA-125/CP2 and CA-125/CA19-9 were significantly different after either chemotherapy or recurrence.Conclusions Serum tumor marker expression in patients with EOC or PSPC may change after chemotherapy or recurrence,indicating that in addition to the markers that are abnormal before surgery,those markers that are normalshould also be monitored during chemotherapy and follow-up.
文摘Epithelial ovarian cancer(EOC)is the most lethal gynaecological malignancy in the western world.The majority of women presenting with the disease are asymptomatic and it has been dubbed the“silent killer”.To date there is no effective minimally invasive method of stratifying those with the disease or screening for the disease in the general population.Recent molecular and pathological discoveries,along with the advancement of scientific technology,means there is a real possibility of having disease-specific liquid biopsies available within the clinical environment in the near future.In this review we discuss these discoveries,particularly in relation to the most common and aggressive form of EOC,and their role in making this possibility a reality.
文摘AIM： To determine DNA aneuploidy in mucosal biopsies of achalasia patients for subsequent rapid diagnosis. METHODS： Biopsies from the middle third of the esophagus were obtained in 15 patients with achalasia. Immunohistochemical staining was carried out with monoclonal antibodies MIB-1 for Ki67 and PAb 1801 for p53, in addition to the conventional histologic examination for dysplasia. Nuclei of fresh biopsy material were enzymatically and mechanically isolated, and the DNA content was determined with image cytometry after Feulgen staining. DNA grading of malignancy was assessed according to Boecking to determine the variability of DNA values noted around the normal diploid peak. Further indices measured included the aneuploid rate, and the 5c-, 7c- and 9c-exceeding rate. RESULTS： The histological examination did not demonstrate dysplasia; while MIB-1 （basal） showed a positive reaction in 8/15 achalasia specimens, p53 was negative in all specimens. Image cytometric DNA analysis detected aneuploidy in 4/15 （26.7%） specimens. Samples from 15 patients with squamous cell carcinoma as well as specimens obtained exclusively 2 cm proximal to the tumor served as reference tests. All carcinomas （15/15） as well as 9 of the peritumoral samples （9/15） were aneuploid. The comparison of biopsies from achalasia patients with peritumoral and carcinoma specimens revealed statistically significant differences regarding the aneuploid rate （diploid： P 〈 0.0001; tetraploid： P = 0.001）, grading of malignancy according to Boecking （P 〈 0.0001） and the 5c- （P 〈 0.0001）, 7c-（P 〈 0.0001）, and 9c- （P = 0.0001） exceeding rate with progredient DNA alterations in the respective order. CONCLUSION： The finding that DNA aneuploidy was identified by image cytometry in esophageal specimens of patients with achalasia, which may be due to specific chromosomal alterations presenting as precancerous lesions in 27% of patients, leads us to conclude that image cytometry represents a valuable screening tool.
文摘目的:探讨人食管癌相关基因4(esophageal cancer related gene 4,ECRG4)基因启动子区域在卵巢癌组织中的甲基化状态及临床意义。方法:应用甲基化特异性PCR检测ECRG4基因启动子在50例卵巢癌组织和10例正常卵巢组织中的甲基化状态并结合临床病理资料进行分析。结果:在卵巢癌组织中ECRG4甲基化阳性率为36%(18/50),正常卵巢组织未出现ECRG4甲基化。ECRG4甲基化与肿瘤淋巴结转移及Ki-67表达密切相关(P<0.05)。结论:ECRG4甲基化可能是参与卵巢癌发展的重要分子事件。
文摘目的通过对患者血浆游离DNA的定量检测,探索一种可用于卵巢上皮性癌早期诊断和疗效监控的新方法。方法2001年4月至2003年2月上海市肿瘤研究所等单位以微量基因组抽提试剂盒抽提血浆DNA,以SYBR Green I斑点荧光染色法分别检测93例卵巢上皮性癌、25例卵巢良性肿瘤及100例健康对照标本血浆游离DNA含量。结果卵巢上皮性癌血浆游离DNA质量浓度为(82.1±60.6)μg/L,卵巢良性肿瘤为(21.1±17.6)μg/L,健康对照组为(14.9±8.2)μg/L,卵巢上皮性癌患者血浆游离DNA质量浓度明显高于正常对照及卵巢良性肿瘤,差异有显著性(P<0.001)。血浆游离DNA质量浓度与病理类型及组织学分级无关,但与临床分期相关,IV期癌较其他三期升高明显(P=0.016)。在I期卵巢上皮性癌患者中,血浆游离DNA质量浓度已达(68.8±46.1)μg/L,显著高于卵巢良性肿瘤和健康对照人员(P<0.001)。结论卵巢上皮性癌游离DNA定量检测有可能成为一种新的卵巢上皮性癌血浆标志物检测方法。
